MK-3697
MK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists . MK-3697 is also the third insomnia drug, currently being developed by Merck. MK-3697 has Ki = 0.95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK-3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species.
| Supplier | Ace Therapeutics |
|---|---|
| Product # | SMD1337 |
| CAS # | 1224846-01-8 |
| Pricing | Customizable size, Inquiry |
| Synonym | MK3697; MK-3697; MK 3697. |
| Product Category | Lab-use Small Molecule Drugs |
| Chemical Formula | C23H21N5O3S |
| Exact Mass | 447.13651 |
| Molecular Weight | 447.51 |
| Elemental Analysis | C, 61.73; H, 4.73; N, 15.65; O, 10.73; S, 7.17 |
| IUPAC/Chemical Name | N-((5,6-dimethoxypyridin-2-yl)methyl)-5'-methyl-5-(thiazol-2-yl)-[2,3'-bipyridine]-4-carboxamide. |
| InChi Key | VSOUDUXMPUHJEU-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C23H21N5O3S/c1-14-8-15(11-24-10-14)19-9-17(18(13-26-19)23-25-6-7-32-23)21(29)27-12-16-4-5-20(30-2)22(28-16)31-3/h4-11,13H,12H2,1-3H3,(H,27,29) |
| SMILES Code | O=C(C1=CC(C2=CC(C)=CN=C2)=NC=C1C3=NC=CS3)NCC4=NC(OC)=C(OC)C=C4 |
| Appearance | white solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO, not in water |
| Shelf Life | >2 years if stored properly |
| Drug Formulation | This drug may be formulated in DMSO |
| Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
| HS Tariff Code | 2934.99.9001 |
| Availability | 2 Weeks |